Evidence map›Paper›PMID 17459063›Full record

Trial reportCancer science2007

Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.

Yuji Sato, Toshiyoshi Fujiwara, Takashi Mine, Hiroki Shomura, Shigenori Homma, Yoshiaki Maeda, Naoyuki Tokunaga, Yoshihiro Ikeda, Yuki Ishihara, Akira Yamada and 4 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Colorectal cancer vaccines: Tumor-associated antigensWorld journal of gastroenterology · 2018
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. HLA typing demands for peptide-based anti-cancer vaccine.Cancer immunology, immunotherapy : CII · 2008
    Article
  19. Research Progress of Immunotherapy for Gastric Cancer.Technology in cancer research & treatment
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yuji SatoDepartment of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
Toshiyoshi Fujiwara
Takashi Mine
Hiroki Shomura
Shigenori Homma
Yoshiaki Maeda
Naoyuki Tokunaga
Yoshihiro Ikeda
Yuki Ishihara
Akira Yamada
Noriaki Tanaka
Kyogo Itoh
Mamoru Harada
Satoru Todo
Hokkaido University · JPKurume University · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients. Eleven patients (four with gastric cancer and seven with colorectal cancer) who failed to improve by prior TS-1-based chemotherapies were enrolled in this study. Peptides to be administered to patients were determined based on the presence of peptide-specific cytotoxic T lymphocyte (CTL) precursors in peripheral blood mononuclear cells and peptide-specific IgG in the plasma of cancer patients. Patients were vaccinated with peptides (a maximum of four) biweekly in combination with or without three different doses of TS-1 (20, 40 and 80 mg/m(2)/day). Although grade 3 toxicity, including anemia (one patient) and neutropenia (one patient) were observed, the combination therapy was generally well tolerated. An increase in peptide-specific IgG after the sixth vaccination was observed in the vast majority of patients irrespective of the dose of TS-1 used. In contrast, an increase in peptide-specific interferon-gamma production by CTL was most evident in patients who were administered the highest dose of TS-1. Furthermore, in the patients who received 80 mg/m(2)/day TS-1, CTL-mediated cytotoxicity against cancer cells was maintained at the prevaccination level. These results indicate that administration of the standard dose (80 mg/m(2)/day) of TS-1 in combination with a personalized peptide vaccination does not necessarily impede immunological responses in cancer patients, and could actually maintain or augment them.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCancer VaccinesCell SurvivalColorectal NeoplasmsCombined Modality TherapyFemaleFluorouracilHLA-A24 AntigenHLA-A2 AntigenHLA-A AntigensHumansInterferon-gammaMaleMiddle AgedCancer VaccinesFluorouracilHLA-A24 AntigenHLA-A2 AntigenHLA-A AntigensInterferon-gamma

Identifiers

PMID17459063
PMCPMC11158036
OpenAlexW2012468683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.